66 related articles for article (PubMed ID: 14991544)
1. Expression of constitutively active nuclear-kappa B RelA transcription factor in blasts of acute myeloid leukemia.
Bueso-Ramos CE; Rocha FC; Shishodia S; Medeiros LJ; Kantarjian HM; Vadhan-Raj S; Estrov Z; Smith TL; Nguyen MH; Aggarwal BB
Hum Pathol; 2004 Feb; 35(2):246-53. PubMed ID: 14991544
[TBL] [Abstract][Full Text] [Related]
2. Abnormal B-lymphoblasts in myelodysplastic syndromes and myeloproliferative neoplasms other than chronic myeloid leukemia.
Chan A; Kumar P; Gao Q; Baik J; Sigler A; Londono D; Liu Y; Arcila ME; Dogan A; Zhang Y; Roshal M; Xiao W
Cytometry B Clin Cytom; 2023 May; 104(3):243-252. PubMed ID: 34897961
[TBL] [Abstract][Full Text] [Related]
3. Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging.
Messa E; Carturan S; Maffè C; Pautasso M; Bracco E; Roetto A; Messa F; Arruga F; Defilippi I; Rosso V; Zanone C; Rotolo A; Greco E; Pellegrino RM; Alberti D; Saglio G; Cilloni D
Haematologica; 2010 Aug; 95(8):1308-16. PubMed ID: 20534700
[TBL] [Abstract][Full Text] [Related]
4. Single cell and bulk RNA expression analyses identify enhanced hexosamine biosynthetic pathway and O-GlcNAcylation in acute myeloid leukemia blasts and stem cells.
Schauner R; Cress J; Hong C; Wald D; Ramakrishnan P
Front Immunol; 2024; 15():1327405. PubMed ID: 38601153
[TBL] [Abstract][Full Text] [Related]
5. Aberrant nuclear factor-kappa B activity in acute myeloid leukemia: from molecular pathogenesis to therapeutic target.
Zhou J; Ching YQ; Chng WJ
Oncotarget; 2015 Mar; 6(8):5490-500. PubMed ID: 25823927
[TBL] [Abstract][Full Text] [Related]
6. Novel mitochondria-targeting compounds selectively kill human leukemia cells.
Panina SB; Pei J; Baran N; Tjahjono E; Patel S; Alatrash G; Konoplev S; Stolbov LA; Poroikov VV; Konopleva M; Kirienko NV
Leukemia; 2022 Aug; 36(8):2009-2021. PubMed ID: 35672446
[TBL] [Abstract][Full Text] [Related]
7. A study of nuclear transcription factor-kappa B in childhood autism.
Naik US; Gangadharan C; Abbagani K; Nagalla B; Dasari N; Manna SK
PLoS One; 2011 May; 6(5):e19488. PubMed ID: 21573053
[TBL] [Abstract][Full Text] [Related]
8. Super-enhancer-associated gene CAPG promotes AML progression.
Ma Q; Zhao M; Long B; Li H
Commun Biol; 2023 Jun; 6(1):622. PubMed ID: 37296281
[TBL] [Abstract][Full Text] [Related]
9. GPRC5C drives branched-chain amino acid metabolism in leukemogenesis.
Zhang YW; Velasco-Hernandez T; Mess J; Lalioti ME; Romero-Mulero MC; Obier N; Karantzelis N; Rettkowski J; Schönberger K; Karabacz N; Jäcklein K; Morishima T; Trincado JL; Romecin P; Martinez A; Takizawa H; Shoumariyeh K; Renders S; Zeiser R; Pahl HL; Béliveau F; Hébert J; Lehnertz B; Sauvageau G; Menendez P; Cabezas-Wallscheid N
Blood Adv; 2023 Dec; 7(24):7525-7538. PubMed ID: 37639313
[TBL] [Abstract][Full Text] [Related]
10. Successful ixazomib treatment for relapsed and refractory acute myeloid leukemia transformed from myelodysplastic syndrome.
Oka S; Ono K
Clin Case Rep; 2021 Jun; 9(6):e04287. PubMed ID: 34194792
[TBL] [Abstract][Full Text] [Related]
11. Rapid preparation of high-purity nuclear proteins from a small number of cultured cells for use in electrophoretic mobility shift assays.
Luo Y; Hara T; Ishido Y; Yoshihara A; Oda K; Makino M; Ishii N; Hiroi N; Suzuki K
BMC Immunol; 2014 Dec; 15():586. PubMed ID: 25527077
[TBL] [Abstract][Full Text] [Related]
12. Identification of ILK as a novel therapeutic target for acute and chronic myeloid leukemia.
de la Puente P; Weisberg E; Muz B; Nonami A; Luderer M; Stone RM; Melo JV; Griffin JD; Azab AK
Leuk Res; 2015 Sep; ():. PubMed ID: 26413753
[TBL] [Abstract][Full Text] [Related]
13. In Silico, In Vitro, and In Vivo Evaluation of Caffeine-Coated Nanoparticles as a Promising Therapeutic Avenue for AML through NF-Kappa B and TRAIL Pathways Modulation.
Siddique MH; Bukhari S; Khan IU; Essa A; Ali Z; Sabir U; Ayoub O; Saadia H; Yaseen M; Sultan A; Murtaza I; Kerr PG; Bhat MA; Anees M
Pharmaceuticals (Basel); 2023 Dec; 16(12):. PubMed ID: 38139868
[TBL] [Abstract][Full Text] [Related]
14. Blood group discrepancy in chronic myeloid leukemia.
Subramaniyan R
Med J Armed Forces India; 2023; 79(2):244-246. PubMed ID: 36969127
[No Abstract] [Full Text] [Related]
15. The Molecular Context of Oxidant Stress Response in Cancer Establishes ALDH1A1 as a Critical Target: What This Means for Acute Myeloid Leukemia.
Dancik GM; Varisli L; Vlahopoulos SA
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298333
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of cystathionine β-synthase promotes apoptosis and reduces cell proliferation in chronic myeloid leukemia.
Wang D; Yang H; Zhang Y; Hu R; Hu D; Wang Q; Liu Y; Liu M; Meng Z; Zhou W; Song W
Signal Transduct Target Ther; 2021 Feb; 6(1):52. PubMed ID: 33558454
[TBL] [Abstract][Full Text] [Related]
17. PIM Kinase Inhibitors Block the Growth of Primary T-cell Acute Lymphoblastic Leukemia: Resistance Pathways Identified by Network Modeling Analysis.
Lim JT; Singh N; Leuvano LA; Calvert VS; Petricoin EF; Teachey DT; Lock RB; Padi M; Kraft AS; Padi SKR
Mol Cancer Ther; 2020 Sep; 19(9):1809-1821. PubMed ID: 32753387
[TBL] [Abstract][Full Text] [Related]
18. Arsenic trioxide induces the apoptosis and decreases NF-κB expression in lymphoma cell lines.
Zhong L; Xu F; Chen F
Oncol Lett; 2018 Nov; 16(5):6267-6274. PubMed ID: 30333888
[TBL] [Abstract][Full Text] [Related]
19. An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes.
Daher M; Hidalgo Lopez JE; Randhawa JK; Jabbar KJ; Wei Y; Pemmaraju N; Borthakur G; Kadia T; Konopleva M; Kantarjian HM; Hearn K; Estrov Z; Reyes S; Bueso-Ramos CE; Garcia-Manero G
Am J Hematol; 2017 Jul; 92(7):674-682. PubMed ID: 28370157
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
